Clinical trials in Perugia

283 clinical trials in Perugia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Perugia at a glance

283

clinical trials

Research sites2

Quick filters

283 trials in Perugia

Open in trial search

Non-small cell lung cancer stage I

Recruiting

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Povorcitinib
Sponsor:Incyte Corp.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Selatogrel
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Divarasib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Adagrasib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Perugia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer, leukemia, and breast cancer treatments. Studies include evaluating new combination therapies and targeted treatments for various cancer types.

Advanced NSCLC treatments with immunotherapy combinations
Novel approaches for acute myeloid leukemia
Breast cancer endocrine therapy optimization

Multiple trials are investigating breakthrough treatments for both early-stage and metastatic cancers.

02 Dermatology Studies

Research focusing on chronic skin conditions, including allergic contact dermatitis, hidradenitis suppurativa, and prurigo nodularis.

Metal allergen patch testing protocols
Innovative treatments for inflammatory skin disorders
Novel therapeutic approaches for chronic skin conditions

Trials aim to improve diagnostic methods and develop targeted therapies for persistent skin conditions.

03 Autoimmune Disorders

Studies examining treatments for various autoimmune conditions, including psoriatic arthritis and non-infectious uveitis.

Evaluation of biological therapies
Novel treatment combinations
Disease progression monitoring

Research focuses on developing more effective treatments with fewer side effects for chronic autoimmune conditions.

Back to Italy All countries